Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 1559 results for do not do recommendations

  1. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  2. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA854

  3. Single-incision short sling mesh insertion for stress urinary incontinence in women (HTG419)

    Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women. This involves putting 2 short slings around the tube that carries urine from the bladder to support it.

    HealthTech guidance
    Published
    12 October 2016
    View recommendations

    Sections for HTG419

  4. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG656/1 Question The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder

    Research recommendation
    Published
    15 November 2019

  5. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA698

  6. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    Recommendation ID NG98/3 Question Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing

    Research recommendation
    Published
    10 December 2018

  7. Molnupiravir for treating COVID-19 (TA1056)

    Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1056

  8. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  9. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

    Technology appraisal guidance
    Published
    1 May 2024
    View recommendations

    Sections for TA967

  10. Extended access to GP services:- Is extended access to GP services, for example during early mornings, evenings and weekends, more clinically and cost effective than standard access?

    Recommendation ID NG94/1 Question Extended access to GP services:- Is extended access to GP services, for example during early mornings

    Research recommendation
    Published
    15 November 2018

  11. What is the most clinically and cost-effective treatment for diverticular disease?

    Recommendation ID NG147/3 Question What is the most clinically and cost-effective treatment for diverticular disease? Any explanatory

    Research recommendation
    Published
    10 February 2020

  12. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    Recommendation ID NG52/2 Question Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In...

    Research recommendation
    Published
    25 August 2016

  13. Management of stable angina in people with evidence of ischaemia on non-invasive functional testing:- Do people with stable angina and evidence of reversible ischaemia on noninvasive functional testing who are on optimal drug treatment benefit from routine coronary angiography with a view to revascularisation?

    Recommendation ID CG126/2 Question Management of stable angina in people with evidence of ischaemia on non-invasive functional testing:-

    Research recommendation
    Published
    9 June 2015

  14. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

    Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA324

  15. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

    HealthTech guidance
    Published
    30 November 2021
    View recommendations

    Sections for HTG601